Home Newsfeeds Goldman Sachs Initiates Coverage On Fate Therapeutics with Sell Rating, Announces Price Target of $10

Goldman Sachs Initiates Coverage On Fate Therapeutics with Sell Rating, Announces Price Target of $10

Goldman Sachs analyst Andrea Tan initiates coverage on Fate Therapeutics (NASDAQ:FATE) with a Sell rating and announces Price Target of $10.

byBenzinga Newsdesk

December 15, 2022

1 minute read

Goldman Sachs analyst Andrea Tan initiates coverage on Fate Therapeutics (NASDAQ:FATE) with a Sell rating and announces Price Target of $10.

News

‘Apollo Asks VCs To Back Its Bid For Silicon Valley Bank Assets’ – The Information

By Happy Mohamed

March 14, 3:54 PM

https://www.theinformation.com/articles/apollo-asks-vcs-to-back-its-bid-for-silicon-valley-bank-assets

SIVB

Bitcoin Falls Below $63,000; Conflux, Maker Among Top Losers

By Avi Kapoor

April 29, 9:30 AM

Bitcoin (CRYPTO: BTC) moved lower, with the cryptocurrency prices trading below the key $63,000 level on Monday. Ethereum (CRYPTO: ETH) also recorded losses, trading below the key $3,200 mark this morning.

$GALA

JP Morgan Maintains Neutral on Oshkosh, Raises Price Target to $85

By Benzinga Newsdesk

October 28, 9:51 AM

JP Morgan analyst Tami Zakaria maintains Oshkosh (NYSE:OSK) with a Neutral and raises the price target from $82 to $85.

OSK

Vuzix Establishes New Offices, Corporate Entities In Germany & Japan To Cut Costs

By Akanksha Bakshi

April 24, 10:59 AM

Vuzix Corporation (NASDAQ:VUZI) has established new offices and corporate entities in Germany and Japan. The new international infrastructure developments will…

VUZI

Goldman Sachs Initiates Coverage On Fate Therapeutics with Sell Rating, Announces Price Target of $10

Related Posts

‘Apollo Asks VCs To Back Its Bid For Silicon Valley Bank Assets’ – The Information

Bitcoin Falls Below $63,000; Conflux, Maker Among Top Losers

JP Morgan Maintains Neutral on Oshkosh, Raises Price Target to $85

Vuzix Establishes New Offices, Corporate Entities In Germany & Japan To Cut Costs